CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Doxycyclinedrug
Likely dose
Doxycycline 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06582966
NCT06582966Phase 4Completed
CompareCT.gov

Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya

University of Washington·interventional·Posted Sep 3, 2024·Updated Apr 13, 2026

In Brief

A Phase 4 clinical trial evaluating Doxycycline for STI. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The first study of doxycycline postexposure prophylaxis for cisgender women did not reduce incident STIs likely due to low use of doxycycline. Researchers will conduct a pilot study of once-weekly doxyxycline to prevent bacterial STIs among Kenyan cisgender women using PrEP for HIV prevention.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSTI
CountriesKenya
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
20252026
First PostedSep 3, 2024
Enrollment StartAug 13, 2024
Primary CompletionMay 27, 2025
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 1.8 years ago

Interventions

Doxycyclinedrug

Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.